

# INPLASY PROTOCOL

To cite: Yu et al. Circulating growth differentiation factor-15 concentration and hypertension risk: A dose-response meta-analysis. Inplasy protocol 202330082. doi: 10.37766/inplasy2023.3.0082

Received: 23 March 2023

Published: 23 March 2023

**Corresponding author:**  
Zhongwei Zhou

zzw2858@njmu.edu.cn

**Author Affiliation:**  
The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital.

**Support:** None.

**Review Stage at time of this submission:** Preliminary searches.

**Conflicts of interest:**  
None declared.

## Circulating growth differentiation factor-15 concentration and hypertension risk: A dose-response meta-analysis

Yu, ZQ<sup>1</sup>; Liu, HL<sup>2</sup>; Zhou, ZW<sup>3</sup>; Li, L<sup>4</sup>; Hu, SQ<sup>5</sup>.

**Review question / Objective:** GDF-15 is also referred to as macrophage inhibitory cytokine-1, and is a member of the superfamily of transforming growth factors. It has been shown that GDF-15 regulates appetite, body weight, glycolipid metabolism, and infection protection. In several prospective studies, increased circulating GDF-15 levels were found to be an excellent predictor of adverse clinical outcomes, including cardiovascular events and all-cause mortality. However, GDF-15 hasn't been studied extensively to determine its ability to predict hypertension risks in the current studies. The objective of this meta-analysis was to evaluate systematically the dose-response relationship between GDF-15 and hypertension prevalence.

**Information sources:** Information sources will be found by searching the electronic databases Pubmed, EMBASE, and Web of Science.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 23 March 2023 and was last updated on 21 March 2024 (registration number INPLASY202330082).

### INTRODUCTION

**Review question / Objective:** GDF-15 is also referred to as macrophage inhibitory cytokine-1, and is a member of the superfamily of transforming growth factors. It has been shown that GDF-15 regulates

appetite, body weight, glycolipid metabolism, and infection protection. In several prospective studies, increased circulating GDF-15 levels were found to be an excellent predictor of adverse clinical outcomes, including cardiovascular events and all-cause mortality. However, GDF-15

---

hasn't been studied extensively to determine its ability to predict hypertension risks in the current studies. The objective of this meta-analysis was to evaluate systematically the dose-response relationship between GDF-15 and hypertension prevalence.

**Condition being studied:** Although no prospective studies have examined whether circulating GDF-15 contributes to hypertension, many studies have been conducted in the past decade examining the prevalence of hypertension in different populations based on the distribution of GDF-15.

## METHODS

**Participant or population:** No matter what population was studied, studies were eligible if they reported the percentage of hypertension in at least three GDF-15 categories.

**Intervention:** Circulating GDF-15 will be main Exposure/Interventions.

**Comparator:** Comparing the high versus low, or per 1 ng/mL increase in GDF-15 concentration.

**Study designs to be included:** Any study design.

**Eligibility criteria:** At least three categories of GDF-15 hypertension were required for studies to be eligible.

**Information sources:** Information sources will be found by searching the electronic databases Pubmed, EMBASE, and Web of Science.

**Main outcome(s):** The combined effects were estimated using odds ratios (ORs) and 95% confidence intervals (CIs). Furthermore, all studies included in the analysis will have dose-response curves plotted.

**Quality assessment / Risk of bias analysis:** Study quality of the included studies will be

assessed using the Newcastle-Ottawa Scale (NOS) for the included studies.

**Strategy of data synthesis:** Based on heterogeneity among studies, fixed-effects or random-effects models will be used to estimate the pooled effect size.

**Subgroup analysis:** There will be a subgroup analysis based on the study region, sample size, sample types, and GDF-15 detection method used in the study.

**Sensitivity analysis:** By removing one study at a time, sensitivity analyses will be conducted to confirm the stability of the overall pooled OR.

**Country(ies) involved:** China.

**Keywords:** GDF-15; hypertension prevalence; dose-response; meta-analysis.

### Contributions of each author:

Author 1 - Zhengqing Yu.

Author 2 - Hongli Liu.

Author 3 - Zhongwei Zhou.

Author 4 - Li Li.

Author 5 - Sanqiang Hu.